An Afternoon of Innovation: Stratified and Personalised Therapies

AGENDA:

16.00 - 16.50 - Keynote

16.50 - 17.30 - Panel Discussion

17.30 – 19.00 - Reception and Networking

KEYNOTE Speaker:

Dr John McCafferty is a co-Founder of Cambridge Antibody Technology (now MedImmune, Cambridge) alongside Sir Gregory Winter and David Chiswell. He is one of the inventors of scFv antibody fragment phage display, his paper was cited when giving the 2018 Nobel prize in chemistry. John is the Founder and CEO of the biotech company IONTAS Ltd, which focuses on the development of novel antibody therapeutics. Employing its proven expertise in all key areas of therapeutic antibody discovery and development.

PANEL Discussion:

Personalised Healthcare; Benefits, Challenges and Opportunities for Innovation.

Panel Chair: Professor Kerry Chester, leads the Antibody Engineering Group at the UCL Cancer Institute. She has over twenty years’ experience in antibody engineering and antibody phage-display technology. Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets. The work is largely translational; her group designed and manufactured the first scFv to enter clinical trials.

Panel Expert: Sir Alastair Kent OBE, Former Director of Genetic Alliance UK, Chair of Rare Disease UK and Member of the RDUK advisory group to NHS England. Alastair has been awarded an OBE for services to healthcare (2011), FRSA for outstanding contribution to supporting families with genetic conditions (2017), Communique Awards Healthcare Advocate of the Year (2017) and a Lifetime Achievement Award from Eurordis (2018).

Panel Expert: Dr Vaughan Thomas, Visiting Professor at UCL, Outreach Manager for the EPSRC Future Targeted Healthcare Manufacturing Hub and Bioprocess Consultant at Tilingbourne Consulting. Vaughan has over 20 years experience in the biotechnology sector covering all aspects of the industry. As well as leading process design teams on major projects for Biogen, Lonza, Centocor, Eli Lilly and Hoechst.

Panel Expert: Dr Evi Dimitriadou, Senior Program Manager, Innovation Projects at Lonza Biologics